ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

Pharmacogenomics and Personalized Medicine

Volumn 5, Issue 1, 2012, Pages 53-62

  Barratt, Daniel T ^a   Coller, Janet K ^a   Hallinan, Richard ^b   Byrne, Andrew ^b   White, Jason M ^a   Foster, David J R ^c   Somogyi, Andrew A ^a,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Byrne Surgery   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

ABCB1; Methadone; Mu; Opiate substitution treatment; Opioid; OPRM1; P glycoprotein; Receptors

Indexed keywords

METHADONE;

ABCB1 GENE; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; GENE; GENE INTERACTION; GENE ISOLATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MALE; OPIATE ADDICTION; OPRM1 GENE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84861151893     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S29272     Document Type: Article

References (43)

1. Mattick R, Digiusto E, Doran C, et al. National Evaluation of Pharmacotherapies for Opioid Dependence: Report of Results and Recommendations. Sydney, Australia: National Drug and Alcohol Research Centre; 2001.
2. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80(6): 668-681.
3. Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther. 1999;65(6):685-694.
4. Dyer KR, White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction. 1997;92(11):1445-1455.
5. Foster DJR, Somogyi AA, White JM, Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2004;57(6):742-755.
6. Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend. 2006;81(1):55-61.
7. Australian Institute of Health and Welfare. Statistics on Drug Use in Australia 2006. Canberra, Australia: Australian Institute of Health and Welfare; 2007.
8. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81(3):429-444.
9. Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81(5):719-728.
10. Uehlinger C, Crettol S, Chassot P, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol. 2007;27(3):273-278.
11. Fonseca F, de la Torre R, Diaz L, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011;6(5):e19527.
12. Coller JK, Joergensen C, Foster DJ, et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int J Clin Pharmacol Ther. 2007;45(7):410-417.
13. Hassan HE, Myers AL, Coop A, Eddington ND. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci. 2009;98(12): 4928-4940.
14. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2009:1-11.
15. Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev. 2003;35(4):417-454.
16. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42(1):59-98.
17. Tournier N, Decleves X, Saubamea B, Scherrmann JM, Cisternino S. Opioid transport by ATP-binding cassette (ABC) transporters at the blood-brain barrier: implications for neuropsychopharmacology. Curr Pharm Des. 2011;17(26):2829-2842.
18. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006;80(6): 682-690.
19. Crettol S, Deglon JJ, Besson J, et al. No influence of ABCB1 haplotypes on methadone dosage requirement. Clin Pharmacol Ther. 2008;83(5):668-669; author reply 669-670.
20. Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008;17(14):2219-2227.
21. Coller JK, Barratt DT, Somogyi AA. Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clin Pharmacol Ther. 2008;83(5):669-670.
22. Crettol S, Besson J, Croquette-Krokar M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1722-1727.
23. Oertel BG, Kettner M, Scholich K, et al. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284(10):6530-6535.
24. Kasai S, Ikeda K. Pharmacogenomics of the human micro-opioid receptor. Pharmacogenomics. 2011;12(9):1305-1320.
25. Lötsch J, Skarke C, Wieting J, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006;79(1):72-89.
26. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/ MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83(4):559-566.
27. Hurley M, White J, Chadderton T, et al. Guide for Pharmacists: Addiction Treatment and Maintenance Pharmacotherapy (Methadone and Buprenorphine) Programs in South Australia. Adelaide, Australia: Drug and Alcohol Services South Australia; 2010.
28. NSW Department of Health. New South Wales Opioid Treatment Program: Clinical Guidelines for Methadone and Buprenorphine Treatment of Opioid Dependence. North Sydney, Australia: Mental Health and Drug and Alcohol Office, NSW Department of Health; 2006.
29. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69(3):169-174.
30. Coller JK, Beardsley J, Bignold J, et al. Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. Pharmacogenomics Pers Med. 2009;2(1):9-19.
31. Stephens M, Donnely P. A comparison of Bayesian methods for haplotype reconstruction. Am J Hum Genet. 2003;73(5):1162-1169.
32. Stephens M, Smith N, Donnely P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978-989.
33. Aird RE, Thomson M, Macpherson JS, Thurston DE, Jodrell DI, Guichard SM. ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136. Pharmacogenomics J. 2008;8(4):289-296.
34. Salama NN, Yang Z, Bui T, Ho RJ. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci. 2006;95(10): 2293-2308.
35. Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther. 2008;325(2):435-442.
36. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007; 315(5811):525-528.
37. Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol. 2003;65(11):1843-1852.
38. Doehring A, Hentig N, Graff J, et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics. 2009;19(6):407-414.
39. Levran O, Peles E, Hamon S, et al. Nerve growth factor beta polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. Pharmacogenomics J. March 1, 2011. [Epub ahead of print.]
40. Fonseca F, Gratacos M, Escaramis G, et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14(3):171-178.
41. Oneda B, Crettol S, Bochud M, et al. beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 2011;11(4):258-266.
42. Lotsch J, Pruss H, Veh RW, Doehring A. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics. 2010;20(5):291-297.
43. Hung CC, Chiou MH, Huang BH, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011; 12(11):1525-1533.